Myositis - Pipeline Insight, 2021
This report can be delivered to the clients within 3-5 business days
DelveInsight’s, “Myositis - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Myositis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Myositis: Overview
The term “myositis” refers to a general inflammation or swelling of the muscle. Many people have experienced sore muscles after vigorous exercise, a condition that is temporary and improves with rest. Other conditions that can cause muscle weakness and pain include infection, muscle injury from medications, inherited diseases, electrolyte imbalances, and thyroid disease. More often, however, the term myositis is used to refer to a disease involving chronic inflammation of the muscles, often occurring together with other symptoms. This condition is also known as idiopathic inflammatory myopathy (IIM). The disease is highly variable and has been classified into a number of forms, including: Dermatomyositis (DM), Polymyositis (PM), Necrotizing myopathy (NM), Sporadic inclusion body myositis (sIBM), Juvenile forms of myositis (JM). Myositis is often difficult to diagnose, because many physicians are unfamiliar with the disease and its symptoms. A typical diagnosis process for myositis patients begins with a medical history and physical examination. It may also include blood tests, muscle and skin biopsies, and a variety of other diagnostic tests.
'Myositis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Myositis pipeline landscape is provided which includes the disease overview and Myositis treatment guidelines. The assessment part of the report embraces, in depth Myositis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myositis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Myositis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Myositis Emerging Drugs
Further product details are provided in the report.
Myositis: Therapeutic Assessment
This segment of the report provides insights about the different Myositis drugs segregated based on following parameters that define the scope of the report, such as:
Myositis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Myositis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myositis drugs.
Myositis Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Myositis - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Myositis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Myositis: Overview
The term “myositis” refers to a general inflammation or swelling of the muscle. Many people have experienced sore muscles after vigorous exercise, a condition that is temporary and improves with rest. Other conditions that can cause muscle weakness and pain include infection, muscle injury from medications, inherited diseases, electrolyte imbalances, and thyroid disease. More often, however, the term myositis is used to refer to a disease involving chronic inflammation of the muscles, often occurring together with other symptoms. This condition is also known as idiopathic inflammatory myopathy (IIM). The disease is highly variable and has been classified into a number of forms, including: Dermatomyositis (DM), Polymyositis (PM), Necrotizing myopathy (NM), Sporadic inclusion body myositis (sIBM), Juvenile forms of myositis (JM). Myositis is often difficult to diagnose, because many physicians are unfamiliar with the disease and its symptoms. A typical diagnosis process for myositis patients begins with a medical history and physical examination. It may also include blood tests, muscle and skin biopsies, and a variety of other diagnostic tests.
'Myositis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Myositis pipeline landscape is provided which includes the disease overview and Myositis treatment guidelines. The assessment part of the report embraces, in depth Myositis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myositis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Myositis R&D. The therapies under development are focused on novel approaches to treat/improve Myositis.
This segment of the Myositis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Myositis Emerging Drugs
- Lenabasum: Corbus Pharmaceuticals
- Belimumab: GlaxoSmithKline
Further product details are provided in the report.
Myositis: Therapeutic Assessment
This segment of the report provides insights about the different Myositis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Myositis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Myositis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Myositis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myositis drugs.
Myositis Report Insights
- Myositis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Myositis drugs?
- How many Myositis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Myositis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Myositis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Myositis and their status?
- What are the key designations that have been granted to the emerging drugs?
- GlaxoSmithKline
- Corbus Pharmaceuticals
- Abcuro, Inc.
- Orphazyme
- Bristol-Myers Squibb
- Kezar Life Sciences, Inc.
- Viela Bio
- Paean Biotechnology Inc.
- Alexion Pharmaceuticals
- Janssen Biotech
- CSL Behring
- Pfizer
- Restem, LLC.
- Roche
- Belimumab
- Lenabasum
- ABC008
- Abatacept
- KZR-616
- MEDI7734
- PN-101
- Ravulizumab
- tocilizumab
- PF-06823859
- Ustekinumab
Introduction
Executive Summary
Myositis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Myositis – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Lenabasum: Corbus Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Mid Stage Products (Phase II)
Comparative Analysis
KZR-616: Kezar Life Sciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Early Stage Products (Phase I)
Comparative Analysis
ABC 008: Abcuro
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Myositis Key Companies
Myositis Key Products
Myositis- Unmet Needs
Myositis- Market Drivers and Barriers
Myositis- Future Perspectives and Conclusion
Myositis Analyst Views
Myositis Key Companies
Appendix
Executive Summary
Myositis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Myositis – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Lenabasum: Corbus Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Mid Stage Products (Phase II)
Comparative Analysis
KZR-616: Kezar Life Sciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Early Stage Products (Phase I)
Comparative Analysis
ABC 008: Abcuro
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Myositis Key Companies
Myositis Key Products
Myositis- Unmet Needs
Myositis- Market Drivers and Barriers
Myositis- Future Perspectives and Conclusion
Myositis Analyst Views
Myositis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Myositis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Myositis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Myositis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Myositis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
